South Korea · Delayed Price · Currency is KRW REYON Pharmaceutical Statistics
Total Valuation
KRX:102460 has a market cap or net worth of KRW 184.14 billion. The enterprise value is 393.96 billion.
| Market Cap | 184.14B |
| Enterprise Value | 393.96B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:102460 has 18.34 million shares outstanding. The number of shares has decreased by -0.24% in one year.
| Current Share Class | 18.34M |
| Shares Outstanding | 18.34M |
| Shares Change (YoY) | -0.24% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 81.15% |
| Owned by Institutions (%) | 3.13% |
| Float | 2.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.28 |
| PB Ratio | 0.94 |
| P/TBV Ratio | 0.95 |
| P/FCF Ratio | 156.37 |
| P/OCF Ratio | 29.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 110.00, with an EV/FCF ratio of 334.55.
| EV / Earnings | n/a |
| EV / Sales | 2.75 |
| EV / EBITDA | 110.00 |
| EV / EBIT | n/a |
| EV / FCF | 334.55 |
Financial Position
The company has a current ratio of 0.50, with a Debt / Equity ratio of 1.11.
| Current Ratio | 0.50 |
| Quick Ratio | 0.26 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | 127.87 |
| Debt / FCF | 184.15 |
| Interest Coverage | -2.20 |
Financial Efficiency
Return on equity (ROE) is -15.86% and return on invested capital (ROIC) is -7.30%.
| Return on Equity (ROE) | -15.86% |
| Return on Assets (ROA) | -4.11% |
| Return on Invested Capital (ROIC) | -7.30% |
| Return on Capital Employed (ROCE) | -10.58% |
| Weighted Average Cost of Capital (WACC) | 5.86% |
| Revenue Per Employee | 311.01M |
| Profits Per Employee | -74.28M |
| Employee Count | 440 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 2.98 |
Taxes
In the past 12 months, KRX:102460 has paid 1.99 billion in taxes.
| Income Tax | 1.99B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.77% in the last 52 weeks. The beta is 0.47, so KRX:102460's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -14.77% |
| 50-Day Moving Average | 10,034.40 |
| 200-Day Moving Average | 10,620.30 |
| Relative Strength Index (RSI) | 51.54 |
| Average Volume (20 Days) | 35,042 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:102460 had revenue of KRW 143.37 billion and -34.24 billion in losses. Loss per share was -1,867.11.
| Revenue | 143.37B |
| Gross Profit | 36.47B |
| Operating Income | -30.26B |
| Pretax Income | -32.26B |
| Net Income | -34.24B |
| EBITDA | 1.70B |
| EBIT | -30.26B |
| Loss Per Share | -1,867.11 |
Balance Sheet
The company has 7.04 billion in cash and 216.85 billion in debt, with a net cash position of -209.82 billion or -11,439.74 per share.
| Cash & Cash Equivalents | 7.04B |
| Total Debt | 216.85B |
| Net Cash | -209.82B |
| Net Cash Per Share | -11,439.74 |
| Equity (Book Value) | 194.87B |
| Book Value Per Share | 10,624.82 |
| Working Capital | -79.81B |
Cash Flow
In the last 12 months, operating cash flow was 6.22 billion and capital expenditures -5.04 billion, giving a free cash flow of 1.18 billion.
| Operating Cash Flow | 6.22B |
| Capital Expenditures | -5.04B |
| Depreciation & Amortization | 31.95B |
| Net Borrowing | -3.14B |
| Free Cash Flow | 1.18B |
| FCF Per Share | 64.21 |
Margins
Gross margin is 25.44%, with operating and profit margins of -21.10% and -23.88%.
| Gross Margin | 25.44% |
| Operating Margin | -21.10% |
| Pretax Margin | -22.50% |
| Profit Margin | -23.88% |
| EBITDA Margin | 1.18% |
| EBIT Margin | -21.10% |
| FCF Margin | 0.82% |
Dividends & Yields
KRX:102460 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.24% |
| Shareholder Yield | 0.24% |
| Earnings Yield | -18.60% |
| FCF Yield | 0.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 29, 2020. It was a forward split with a ratio of 1.02.
| Last Split Date | Dec 29, 2020 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
KRX:102460 has an Altman Z-Score of 0.87 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.87 |
| Piotroski F-Score | 4 |